Cargando…

Traditional Chinese medicine for the treatment of diabetic kidney disease: A study-level pooled analysis of 44 randomized controlled trials

Background: Accumulating evidence suggests that traditional Chinese medicine (TCM) has significant effects on reducing 24-h urinary protein (24-h UPRO) and improves renal function indices. The current level of evidence-based medicine is still not enough due to the limitation of clinical center size...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xuele, Ge, Minyao, Zhai, Xinyu, Xiao, Yang, Zhang, Yaheng, Xu, Ziling, Zhou, Zhiguang, Mei, Zubing, Yang, Xuejun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606328/
https://www.ncbi.nlm.nih.gov/pubmed/36313382
http://dx.doi.org/10.3389/fphar.2022.1009571
_version_ 1784818272681590784
author Liu, Xuele
Ge, Minyao
Zhai, Xinyu
Xiao, Yang
Zhang, Yaheng
Xu, Ziling
Zhou, Zhiguang
Mei, Zubing
Yang, Xuejun
author_facet Liu, Xuele
Ge, Minyao
Zhai, Xinyu
Xiao, Yang
Zhang, Yaheng
Xu, Ziling
Zhou, Zhiguang
Mei, Zubing
Yang, Xuejun
author_sort Liu, Xuele
collection PubMed
description Background: Accumulating evidence suggests that traditional Chinese medicine (TCM) has significant effects on reducing 24-h urinary protein (24-h UPRO) and improves renal function indices. The current level of evidence-based medicine is still not enough due to the limitation of clinical center size and sample size. Objective: We aimed to update the current evidence on the efficacy of TCM in the treatment of diabetic kidney disease (DKD). Methods: PubMed, Embase, the Cochrane Library, and SinoMed were searched to identify randomized controlled trials (RCTs) comparing the clinical efficacy of TCM combined with Western medicine with that of Western medicine alone for the treatment of DKD. The main outcome measure was 24-h UPRO. The secondary outcomes were serum creatinine (Scr), blood urea nitrogen (BUN), glycosylated hemoglobin (HbA1c), fasting blood glucose (FBG), total cholesterol (TC), and triglyceride (TG). Meta-analyses were performed using random-effects models. The revised Cochrane risk-of-bias tool was used to assess the risk of bias. Results: A total of 44 RCTs with 3,730 participants were included. The summary estimates showed that compared with Western medicine alone, TCM combined with Western medicine significantly improved 24-h UPRO [standardized mean difference (SMD) −1.10, 95% confidence interval (CI) −1.45 to −0.74]. Moreover, TCM combined with Western medicine significantly reduced the levels of other renal function indices, including Scr (SMD −1.25, 95% CI: −1.69 to −0.81) and BUN (SMD −0.75, 95% CI: −1.10 to −0.40). TCM combined with Western medicine also showed greater benefits in reducing the levels of FBG (SMD −0.31, 95% CI: −0.47 to −0.15) and HbA1c (SMD −0.62, 95% CI: −0.89 to −0.36) in patients with DKD. In addition, superior effects on the lipid profile were noted in the TCM combined with Western medicine group in terms of TG (SMD −1.17, 95% CI: −1.76 to −0.59) and TC (SMD −0.95, 95% CI: −1.43 to −0.47). The risk of bias could have resulted from selective reports, unclear randomization methods, unblinded assignments, and some missing data. Conclusion: The results of this meta-analysis suggest that TCM combined with Western medicine has significant effects on reducing 24-h UPRO and improves renal function indices and lipid profiles compared with Western medicine alone for DKD. However, the results should be interpreted with caution due to the risk of bias of the included trials. Systematic Review Registration: [https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=213199], identifier [CRD: 42020213199].
format Online
Article
Text
id pubmed-9606328
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96063282022-10-28 Traditional Chinese medicine for the treatment of diabetic kidney disease: A study-level pooled analysis of 44 randomized controlled trials Liu, Xuele Ge, Minyao Zhai, Xinyu Xiao, Yang Zhang, Yaheng Xu, Ziling Zhou, Zhiguang Mei, Zubing Yang, Xuejun Front Pharmacol Pharmacology Background: Accumulating evidence suggests that traditional Chinese medicine (TCM) has significant effects on reducing 24-h urinary protein (24-h UPRO) and improves renal function indices. The current level of evidence-based medicine is still not enough due to the limitation of clinical center size and sample size. Objective: We aimed to update the current evidence on the efficacy of TCM in the treatment of diabetic kidney disease (DKD). Methods: PubMed, Embase, the Cochrane Library, and SinoMed were searched to identify randomized controlled trials (RCTs) comparing the clinical efficacy of TCM combined with Western medicine with that of Western medicine alone for the treatment of DKD. The main outcome measure was 24-h UPRO. The secondary outcomes were serum creatinine (Scr), blood urea nitrogen (BUN), glycosylated hemoglobin (HbA1c), fasting blood glucose (FBG), total cholesterol (TC), and triglyceride (TG). Meta-analyses were performed using random-effects models. The revised Cochrane risk-of-bias tool was used to assess the risk of bias. Results: A total of 44 RCTs with 3,730 participants were included. The summary estimates showed that compared with Western medicine alone, TCM combined with Western medicine significantly improved 24-h UPRO [standardized mean difference (SMD) −1.10, 95% confidence interval (CI) −1.45 to −0.74]. Moreover, TCM combined with Western medicine significantly reduced the levels of other renal function indices, including Scr (SMD −1.25, 95% CI: −1.69 to −0.81) and BUN (SMD −0.75, 95% CI: −1.10 to −0.40). TCM combined with Western medicine also showed greater benefits in reducing the levels of FBG (SMD −0.31, 95% CI: −0.47 to −0.15) and HbA1c (SMD −0.62, 95% CI: −0.89 to −0.36) in patients with DKD. In addition, superior effects on the lipid profile were noted in the TCM combined with Western medicine group in terms of TG (SMD −1.17, 95% CI: −1.76 to −0.59) and TC (SMD −0.95, 95% CI: −1.43 to −0.47). The risk of bias could have resulted from selective reports, unclear randomization methods, unblinded assignments, and some missing data. Conclusion: The results of this meta-analysis suggest that TCM combined with Western medicine has significant effects on reducing 24-h UPRO and improves renal function indices and lipid profiles compared with Western medicine alone for DKD. However, the results should be interpreted with caution due to the risk of bias of the included trials. Systematic Review Registration: [https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=213199], identifier [CRD: 42020213199]. Frontiers Media S.A. 2022-10-13 /pmc/articles/PMC9606328/ /pubmed/36313382 http://dx.doi.org/10.3389/fphar.2022.1009571 Text en Copyright © 2022 Liu, Ge, Zhai, Xiao, Zhang, Xu, Zhou, Mei and Yang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Liu, Xuele
Ge, Minyao
Zhai, Xinyu
Xiao, Yang
Zhang, Yaheng
Xu, Ziling
Zhou, Zhiguang
Mei, Zubing
Yang, Xuejun
Traditional Chinese medicine for the treatment of diabetic kidney disease: A study-level pooled analysis of 44 randomized controlled trials
title Traditional Chinese medicine for the treatment of diabetic kidney disease: A study-level pooled analysis of 44 randomized controlled trials
title_full Traditional Chinese medicine for the treatment of diabetic kidney disease: A study-level pooled analysis of 44 randomized controlled trials
title_fullStr Traditional Chinese medicine for the treatment of diabetic kidney disease: A study-level pooled analysis of 44 randomized controlled trials
title_full_unstemmed Traditional Chinese medicine for the treatment of diabetic kidney disease: A study-level pooled analysis of 44 randomized controlled trials
title_short Traditional Chinese medicine for the treatment of diabetic kidney disease: A study-level pooled analysis of 44 randomized controlled trials
title_sort traditional chinese medicine for the treatment of diabetic kidney disease: a study-level pooled analysis of 44 randomized controlled trials
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606328/
https://www.ncbi.nlm.nih.gov/pubmed/36313382
http://dx.doi.org/10.3389/fphar.2022.1009571
work_keys_str_mv AT liuxuele traditionalchinesemedicineforthetreatmentofdiabetickidneydiseaseastudylevelpooledanalysisof44randomizedcontrolledtrials
AT geminyao traditionalchinesemedicineforthetreatmentofdiabetickidneydiseaseastudylevelpooledanalysisof44randomizedcontrolledtrials
AT zhaixinyu traditionalchinesemedicineforthetreatmentofdiabetickidneydiseaseastudylevelpooledanalysisof44randomizedcontrolledtrials
AT xiaoyang traditionalchinesemedicineforthetreatmentofdiabetickidneydiseaseastudylevelpooledanalysisof44randomizedcontrolledtrials
AT zhangyaheng traditionalchinesemedicineforthetreatmentofdiabetickidneydiseaseastudylevelpooledanalysisof44randomizedcontrolledtrials
AT xuziling traditionalchinesemedicineforthetreatmentofdiabetickidneydiseaseastudylevelpooledanalysisof44randomizedcontrolledtrials
AT zhouzhiguang traditionalchinesemedicineforthetreatmentofdiabetickidneydiseaseastudylevelpooledanalysisof44randomizedcontrolledtrials
AT meizubing traditionalchinesemedicineforthetreatmentofdiabetickidneydiseaseastudylevelpooledanalysisof44randomizedcontrolledtrials
AT yangxuejun traditionalchinesemedicineforthetreatmentofdiabetickidneydiseaseastudylevelpooledanalysisof44randomizedcontrolledtrials